Compare EUDA & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | CALC |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 63.0M |
| IPO Year | N/A | N/A |
| Metric | EUDA | CALC |
|---|---|---|
| Price | $2.27 | $4.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 36.8K | ★ 106.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $5,160,280.00 | N/A |
| Revenue This Year | $137.25 | N/A |
| Revenue Next Year | $361.43 | N/A |
| P/E Ratio | $313.71 | ★ N/A |
| Revenue Growth | ★ 83.73 | N/A |
| 52 Week Low | $1.03 | $1.42 |
| 52 Week High | $6.30 | $4.82 |
| Indicator | EUDA | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 70.23 |
| Support Level | $2.81 | $3.65 |
| Resistance Level | $3.21 | $4.74 |
| Average True Range (ATR) | 0.31 | 0.43 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 3.42 | 89.81 |
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.